
Hexagon Bio raises $61M to continue efforts to turn fungi into drugs
A year after raising a $47 million launch round, the fungi-loving drug hunters at Hexagon Bio have more than doubled their coffers.
Hexagon announced today that it raised another $61 million for its efforts to design cancer and infectious disease drugs based on insights mined from the DNA in millions of species of fungi. The new financing brings Hexagon’s committed funding to over $108 million.
Nextech Invest led the financing, along with new investors SoftBank Vision Fund 2 and Casdin Capital. The Column Group, 8VC, and Two Sigma Ventures committed funds as returning investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.